Literature DB >> 24360997

UK-1 and structural analogs are potent inhibitors of hepatitis C virus replication.

Dawn N Ward1, Daniel C Talley1, Mrinalini Tavag1, Samrawit Menji1, Paul Schaughency1, Andrea Baier2, Paul J Smith3.   

Abstract

The bacterial natural product UK-1 and several structural analogs inhibit replication of the hepatitis C virus in the replicon assay, with IC50 values as low as 0.50 μM. The NS3 helicase has been identified as a possible target of inhibition for several of these compounds, while the remaining inhibitors act via an undetermined mechanism. Gel shift assays suggest that helicase inhibition is a direct result of inhibitor-enzyme binding as opposed to direct RNA binding, and the ATPase activity of NS3 is not affected. The syntheses and biological results are presented herein.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Helicase; Hepatitis C; Inhibitor; NS3

Mesh：

Substances：

Year:  2013        PMID： 24360997      PMCID： PMC6136245          DOI： 10.1016/j.bmcl.2013.12.012

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  36 in total

1.  Scope of worldwide hepatitis C problem.

Authors:  Robert S Brown; Paul J Gaglio
Journal:  Liver Transpl       Date:  2003-11       Impact factor: 5.799

2.  NS3 helicase actively separates RNA strands and senses sequence barriers ahead of the opening fork.

Authors:  Wei Cheng; Sophie Dumont; Ignacio Tinoco; Carlos Bustamante
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

3.  New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection.

Authors:  Anna Stankiewicz-Drogon; Larisa G Palchykovska; Valentina G Kostina; Inna V Alexeeva; Anatoly D Shved; Anna M Boguszewska-Chachulska
Journal:  Bioorg Med Chem       Date:  2008-08-31       Impact factor: 3.641

4.  Purification and characterization of West Nile virus nucleoside triphosphatase (NTPase)/helicase: evidence for dissociation of the NTPase and helicase activities of the enzyme.

Authors:  P Borowski; A Niebuhr; O Mueller; M Bretner; K Felczak; T Kulikowski; H Schmitz
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding.

Authors:  J L Kim; K A Morgenstern; J P Griffith; M D Dwyer; J A Thomson; M A Murcko; C Lin; P R Caron
Journal:  Structure       Date:  1998-01-15       Impact factor: 5.006

6.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

7.  Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase.

Authors:  Angela M I Lam; David N Frick
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

8.  Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins.

Authors:  C Failla; L Tomei; R De Francesco
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  The NS4A protein of hepatitis C virus promotes RNA-coupled ATP hydrolysis by the NS3 helicase.

Authors:  Rudolf K F Beran; Brett D Lindenbach; Anna Marie Pyle
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

10.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103
View more
  2 in total

1.  Exploring the biocombinatorial potential of benzoxazoles: generation of novel caboxamycin derivatives.

Authors:  Armando A Losada; Carmen Méndez; José A Salas; Carlos Olano
Journal:  Microb Cell Fact       Date:  2017-05-25       Impact factor: 5.328

2.  Benzimidazole and Benzoxazole Zinc Chelators as Inhibitors of Metallo-β-Lactamase NDM-1.

Authors:  Abigail C Jackson; Tyler B J Pinter; Daniel C Talley; Adnan Baker-Agha; Dhruvil Patel; Paul J Smith; Katherine J Franz
Journal:  ChemMedChem       Date:  2020-11-19       Impact factor: 3.466
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.